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Abstract
Objective To determine the most effective tocolytic agent at delaying
delivery.
Design Systematic review and network meta-analysis.
Data sources Cochrane Central Register of Controlled Trials, Medline,
Medline In-Process, Embase, and CINAHL up to 17 February 2012.
Study selection Randomised controlled trials of tocolytic therapy in
women at risk of preterm delivery.
Data extraction At least two reviewers extracted data on study design,
characteristics, number of participants, and outcomes reported (neonatal
andmaternal). A network meta-analysis was done using a random effects
model with drug class effect. Two sensitivity analyses were carried out
for the primary outcome; restricted to studies at low risk of bias and
restricted to studies excluding women at high risk of preterm delivery
(those with multiple gestation and ruptured membranes).
Results Of the 3263 titles initially identified, 95 randomized controlled
trials of tocolytic therapy were reviewed. Compared with placebo, the
probability of delivery being delayed by 48 hours was highest with
prostaglandin inhibitors (odds ratio 5.39, 95% credible interval 2.14 to
12.34) followed by magnesium sulfate (2.76, 1.58 to 4.94), calcium
channel blockers (2.71, 1.17 to 5.91), beta mimetics (2.41, 1.27 to 4.55),
and the oxytocin receptor blocker atosiban (2.02, 1.10 to 3.80). No class
of tocolytic was significantly superior to placebo in reducing neonatal
respiratory distress syndrome. Compared with placebo, side effects
requiring a change of medication were significantly higher for beta
mimetics (22.68, 7.51 to 73.67), magnesium sulfate (8.15, 2.47 to 27.70),
and calcium channel blockers (3.80, 1.02 to 16.92). Prostaglandin
inhibitors and calcium channel blockers were the tocolytics with the best
probability of being ranked in the top three medication classes for the
outcomes of 48 hour delay in delivery, respiratory distress syndrome,
neonatal mortality, and maternal side effects (all cause).
Conclusions Prostaglandin inhibitors and calcium channel blockers
had the highest probability of delaying delivery and improving neonatal
and maternal outcomes.
Introduction
Tocolytic therapy to delay preterm delivery is an important
intervention in obstetrics. Although tocolytics have not been
shown to improve neonatal outcomes, they can delay preterm
delivery long enough for antenatal corticosteroids to be
administered or for the mother to be transported to a tertiary
care facility.1 In premature neonates, antenatal corticosteroids
reducemorbidity andmortality.2Tocolytic therapymay therefore
have an important role in improving outcomes from preterm
delivery. With over 500 000 preterm births in the United States
alone (12.3% of all births in 2008)3 and 29% of these being less
than 34weeks’ gestation, preterm delivery is an important public
health issue.
Many different classes of drugs have been used for tocolytic
therapy.4 These include beta mimetics such as ritodrine and
terbutaline; magnesium sulfate; prostaglandin inhibitors (for
example, indomethacin, ketorolac); calcium channel blockers
such as nifedipine; nitrates (for example, nitroglycerine);
oxytocin receptor blockers (for example, atosiban), and others.
Each tocolytic has a unique mechanism of action, side effects,
and degree of complexity to administer.5 Several Cochrane
reviews have compared individual tocolytic drugs with placebo
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or other tocolytics.6-10 A recent pooled meta-analysis and
decision analysis of trials on tocolytics showed that to delay
delivery for 48 hours and seven days, prostaglandin inhibitors
were the best first line tocolytic.1 A standard pairwise
meta-analysis, however, can only compare two treatments (or
classes) that have been directly compared in head to head trials
(direct evidence). Consequently, trials comparing two treatments
from the same class are often excluded from class level
meta-analyses. In the absence of a single high quality,
randomized controlled trial comparing all tocolytic therapies,
uncertainty remains about which is themost effective at delaying
preterm delivery.11
For a complex condition such as preterm delivery with multiple
competing treatment options, not all of which have been directly
compared, a network meta-analysis may be better able to allow
for comparisons and conclusions about which tocolytic is most
effective. A network meta-analysis refers to networks of trial
evidence in which all the available direct and indirect evidence
on relative treatment effects are pooled simultaneously in a
single coherent analysis.12 13 Indirect evidence is obtained when
the relative effectiveness of treatment B versus treatment C is
inferred through a common comparator A (see supplementary
file for equation). Thus a network meta-analysis produces
estimates of the relative effects of each treatment compared
with every other in a network, even though some pairs may not
have been directly compared, and has the potential to reduce
the uncertainty in treatment effect estimates.12 It also allows for
the calculation of the probability that each treatment, or class,
is the best for any given outcome. Network meta-analysis can
also be used to identify gaps in the evidence base.14 In an active
area such as tocolysis for preterm delivery, with six trials
published since 2009, a networkmeta-analysis has the potential
to inform future research agendas. We systematically reviewed
and analysed trials on tocolytics and carried out a network
meta-analysis to determine the most effective agent for delaying
preterm delivery.
Methods
Using the search terms “preterm labor”, “tocolytic”, and
“obstetric labor, premature” we systematically searched the
Cochrane Central Register of Controlled Trials (February 2012),
Medline (1950-present), Medline In-Process/Daily Update (17
February 2012), Embase (1988-2012), and CINAHL
(1982-2012) for published randomized controlled trials of
tocolytic therapy. We limited the search to articles reporting
trials in humans, and excluded duplicate trial entries. To ensure
completeness, we cross referenced our search results with the
Cochrane reviews of tocolytic medications, hand searching for
additional titles. We did not register a protocol for the review.
Based on the titles we read the abstracts of potentially relevant
papers and obtained the full text articles for those that seemed
pertinent. Included trials were those that reported a comparison
between different medications or between a medication and a
placebo or usual care for delaying preterm delivery. Trials were
excluded if they were not randomized controlled trials, did not
study women at risk of preterm delivery (defined by trial), did
not study at least one tocolytic drug, used combination drug
therapies for tocolysis, or did not report maternal or neonatal
outcomes in relation to preterm delivery. As published abstracts
did not contain enough information for complete data to be
extracted we did not include them. We also excluded personal
communications cited in Cochrane reviews. At least two
reviewers read the articles and extracted data from the trials.
Discordance between the reviewers was resolved by consensus.
Abstracts of articles in non-English languages were reviewed.
If the article was considered relevant, we obtained the full text
and had it translated for possible data extraction. Published
abstracts from conferences were not included.
Study quality was assigned utilizing the methodology and
categories described in theCochrane CollaborationHandbook.15
The Cochrane collaboration’s recommended tool for assessing
risk of bias is neither a scale nor a checklist but a domain based
evaluation, in which critical assessments are made separately
for different domains. Briefly, the tool for assessing risk of bias
addresses seven specific domains: random sequence generation,
allocation concealment, blinding of participants and personnel,
blinding of outcome assessment, incomplete outcome data,
selective reporting, and other sources of bias. Each domain is
assigned a judgment relating to the risk of bias for that study:
low risk, high risk, and unclear (or unknown). For the purpose
of a planned sensitivity analysis, we counted the total number
of low risk scores (out of 7) for each study. When at least four
domains had a low risk score, with at least one of the domains
needing to be sequence generation or allocation concealment,
we considered the overall study quality to be high.
At least two reviewers extracted data on study design,
characteristics, number of participants, and outcomes reported.
Relevant studies were those that reported on pregnant women
being treated for preterm delivery or at risk of preterm delivery.
Information extracted on the mothers included age, estimated
gestational age at entry into the study and at delivery, and
number with previous preterm births. Primary data extracted
onmaternal outcomes included the numbers of participants with
delivery delayed by 48 hours and the number of side effects (all
causes) from the tocolytics. Secondary maternal outcomes
extracted included the number of participants with delivery
delayed by seven days and until 37 weeks’ gestation, and the
mean number of days by which delivery was delayed. These
secondary outcomes are not considered in this paper owing to
concerns about multiple statistical testing.We assigned a quality
score to each study, the results of which are reported separately.16
We also extracted data on the use of antenatal corticosteroids,
inclusion or exclusion of multiple gestations or ruptured
membranes, and whether or not the tocolytic therapy was short
term (a predefined length of time such as 48 hours or until
contractions stopped) or long term (usually until 36 or 37 weeks
estimated gestational age). Primary neonatal outcomes extracted
were rates of respiratory distress syndrome and death. Secondary
neonatal outcomes extracted were birth weight, chronic lung
disease or bronchopulmonary dysplasia, fetal sepsis,
intraventricular hemorrhage, necrotizing enterocolitis,
hyperbilirubinemia, and premature closure of the ductus
arteriosus. These outcomes were defined in the individual trials.
Because of the way outcomes were reported in the trials we
were unable to report an overall composite score for neonatal
morbidity or mortality.
We classified the drugs as placebo (placebo or usual or standard
care without a tocolytic drug); beta mimetics (ritodrine,
terbutaline, nylidrin, salbutamol, fenoterol, hexoprenaline,
isoxsuprine); calcium channel blockers (nifedipine, nicardipine);
magnesium sulfate; nitrates (nitroglycerine, nitric oxide);
oxytocin receptor blockers (atosiban, barusiban); others (alcohol,
human chorionic gonadotropin, combination tocolytic drugs);
and prostaglandin inhibitors (indomethacin, celecoxib, sulindac,
ketorolac, rofecoxib). Two authors (DMH, PK, or JJMcI) then
examined the complete set of trials to assess whether the
characteristics of the trials and participants were similar enough
to be combined in the network meta-analysis—that is, that the
sets of trials did not differ for distribution of potential effect
modifiers. This assumption of “consistency”17 underpins the
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validity of a network meta-analysis and is akin to an assumption
that the direct and indirect evidence estimate the same
underlying treatment effect variable.
Statistical analysis
The primary effectiveness outcome for the network
meta-analysis was delivery successfully delayed for 48 hours.
We chose this outcome as it was most commonly reported and
is a surrogate for the ability to administer a complete course of
antenatal corticosteroids or to allow for maternal transport to a
tertiary care facility. The secondary outcomes were neonatal
mortality, neonatal respiratory distress syndrome, and all cause
maternal side effects. All are binary outcomes. From the analysis
we excluded studies with zero or 100% events on all arms. A
list of excluded trials is available from the authors.
Analyses were done within a Bayesian framework using
WinBUGS 1.4.3.18 We carried out a random effects network
meta-analysis19-21 to simultaneously compare the 18 treatments
and eight tocolytic classes for each outcome. Where head to
head data were available we also carried out pairwise “direct”
meta-analyses using a random effects model. Heterogeneity was
assessed using the posterior median between trial variance, τ2.
However, for ease of interpretation we report the χ2 test for
heterogeneity and I2 statistic for the pairwise meta-analyses
(these were calculated using Stata). Owing to the lack of power
associated with the χ2 test we used P=0.10 for our assessment
of heterogeneity.15 In the case of two or fewer trials we carried
out a fixed effect meta-analysis. The pairwise meta-analyses
were done using the drug classes and not individual treatments
as the subject of interest. Posterior median odds ratios and 95%
credible intervals were calculated. For the primary outcome we
carried out a planned sensitivity analysis based on risk of bias
assessment. Additional sensitivity analyses examined were
restricted to studies that excludedmultiple gestations or excluded
participants with ruptured membranes. A metaregression
analyzed the impact of planned duration of treatment (acute or
short term tocolysis versus prolonged therapy) on the results.
For the network meta-analysis we implemented a class effect
model where each treatment effect in the same class is assumed
to come from a family of treatment effects with a class specific
mean effect and between treatment variability within class
(assumed equal across all classes).22 23 Further details on
alternative models evaluated are available from the authors
together with theWinBUGS code. Goodness of fit wasmeasured
by the posterior mean of the residual deviance. In a well fitting
model the residual deviance should be close to the number of
data points.24 Owing to the way in which the residual deviance
is calculated, zero cells on the baseline (control) arm can cause
computational difficulties. For the purposes of model selection
we removed these trials but included them in the final model
on which the results are based. A key assumption of network
meta-analysis is that of consistency between the direct and
indirect evidence.17We assessedwhether there was inconsistency
in each of the three networks by comparing a model assuming
consistency with that of an inconsistency model25 using the
deviance information criterion. A difference of 3 or more points
is considered meaningful.26 Convergence was assessed using
two chains and was achieved by 25 000 simulations for delivery
delayed by 48 hours, 30 000 for neonatal mortality and
respiratory distress syndrome, and 35 000 for maternal side
effects (based on the Brooks-Gelman-Rubin diagnostic tool in
WinBUGS).We run a further 50 000 updates after convergence
for delivery delayed by 48 hours, 60 <000 for neonatal mortality
and respiratory distress syndrome, and 70 000 for maternal side
effects. All reported results are based on these further samples.
Results
Of 3263 titles initially identified, 159 full text articles were
retrieved, of which 95 satisfied the study inclusion and exclusion
criteria. Fig 1⇓ summarizes the steps of the systematic review.
Nine articles were translated (four in Chinese, two in French,
and one each in German, Portuguese, and Spanish). One of the
French articles was later excluded for not being a true
randomized controlled trial, leaving eight reports in a language
other than English (8%). Details of the characteristics of the
trials and comparison of the quality of tocolytic studies retrieved
are reported elsewhere.16 Twenty five trials contained a placebo
arm (26%),27-51 60 included beta mimetics
(63%),27-29 31 34-37 39 43 46 48 50 52-98 29 included magnesium sulfate
(31%),29 30 33 38 47 53 56 61 68 80 89 90 93 95 96 99-112 29 included calcium
channel blockers
(31%),43 52 59 63 64 70-72 74 76 78 79 84-86 91 92 94 101-104 106 112-117 18 included
prostaglandin inhibitors (19%),40-42 49 57 73 75 81 88 99 107 109-111 116 118-120
13 included oxytocin receptor blockers (atosiban or barusiban)
(14%),32 44 50 51 54 55 65 66 82 83 87 113 114 four included nitrates
(4%),45 58 100 115 and five included other drugs (5%).47 50 77 88 108
For the outcome of delivery delayed by 48 hours 64 trials
assessing 16 treatments from eight drug classes were eligible
for inclusion in the network meta-analysis. For the outcome of
respiratory distress syndrome 60 trials assessing 19 treatments
from seven drug classes were eligible for inclusion, and for the
outcome maternal side effects (all cause) 68 trials assessing 18
treatments from seven drug classes were eligible for inclusion.
Trials included a mean of 111.9 (SD 108.8, range 20-708)
participants and were published from 1966-2011 (see
supplementary table 1 for details of the trials, along with their
quality assessments). Fig 2⇓ presents the complete network of
the 95 randomised controlled trials on tocolytics. No trials
compared atosiban with magnesium sulfate.
Statistical findings
For each outcome nomeaningful differences in residual deviance
or deviance information criterion values were observed between
the inconsistency and consistencymodels. Furthermore, overlap
was substantial between the direct estimates (where available)
and network meta-analysis estimates (figs 3-6⇓⇓⇓⇓). This
provides support for the assumption of consistency required for
networkmeta-analysis—that is, the estimates for direct treatment
effect agree with those generated from the network
meta-analysis. Direct pairwise meta-analyses involve the trial
results that only directly compare the classes, whereas results
from the network meta-analysis utilize the network calculations
described previously. The class effect model provided an
adequate fit to the data, with a posterior mean residual deviance
of 114.4 (112 data points) for the outcome of delivery delayed
by 48 hours, 82.6 (81 data points) for neonatal mortality, 78.9
(81 data points) for respiratory distress syndrome, and 123.2
(118 data points) for maternal side effects.
Delivery delayed by 48 hours: efficacy
For the outcome delivery delayed by 48 hours 55 studies were
included in the network meta-analysis and 54 in the pairwise
meta-analysis (one trial was excluded as it compared two
treatments from the same class). Direct evidence was available
for 14 class versus class pairwise comparisons. Heterogeneity
was evident in two of the random effects pairwisemeta-analyses,
both of which compared active treatment with placebo (beta
mimetic v placebo, n=4 trials, P=0.08; and magnesium sulfate
v placebo, n=3 trials, P=0.001); the I2 values for these two
comparisons were 50% or more (95% for magnesium sulfate
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versus placebo).Where available, the supplementary file reports
the full results from the pairwise meta-analyses; however, the
posterior median odds ratios (95% credible intervals) are also
shown in fig 3 alongside the posterior median odds ratios for
the full suite of 28 class comparisons available from the network
meta-analysis.
The table⇓ reports the effectiveness of tocolytic therapies and
adverse events from the network meta-analysis using placebo
as the reference class to which all other drug classes were
compared. All active classes were superior to placebo in
successfully delaying delivery by 48 hours, although the
category for others and for nitrates did not achieve conventional
significance. The results from the network meta-analysis also
suggested that prostaglandin inhibitors had a greater beneficial
effect than all the other active classes. However, uncertainty in
these estimates was considerable (table, fig 3, and supplementary
table 3). Calcium channel blockers and magnesium sulfate had
a greater effect than oxytocin receptor blockers, nitrates, beta
mimetics, others, and placebo. Fig 7⇓ shows the distribution of
probabilities of each class being ranked at each of the possible
eight positions. The most efficacious treatment class was
prostaglandin inhibitors, which had an 83% probability of being
the “best” class. This meant there was still a 17% probability
of prostaglandin inhibitors not being the best class. The
probability of being ranked in the top three most efficacious
classes was 96% for prostaglandin inhibitors, 63% for
magnesium sulfate, 57% for calcium channel blockers, 33% for
beta mimetics, 24% for nitrates, 14% for oxytocin receptor
blockers, 13% for others, and 0% for placebo. The probability
of being ranked in the bottom three (least efficacious) was 99%
for placebo, 79% for others, 52% for nitrates, 41% for oxytocin
receptor blockers, 13% for beta mimetics, 10% for calcium
channel blockers, 5% for magnesium sulfate, and 1% for
prostaglandin inhibitors. See supplementary table 4 for the
predicted odds ratios and intervals.
Neonatal mortality
For the outcome neonatal mortality 40 trials were included in
the network meta-analysis and 34 in the pairwise meta-analysis.
Two trials were excluded from the pairwise analysis as they
compared treatments from the same class (beta mimetics). Direct
evidence was available for 13 class versus class pairwise
comparisons (see supplementary appendix 2 for the full results).
Heterogeneity was evident in one of the seven random effects
analyses (beta mimetic v placebo, n=6 trials, P<0.001, I2=78%).
Fig 4 shows the posterior median odds ratios (95% credible
intervals) from each pairwise meta-analysis alongside the
posterior median odds ratios for the full suite of 21 class
comparisons available from the network meta-analysis. The
results from the direct, head to head meta-analyses were
consistent with those of the network meta-analysis.
No clear evidence was found for the relative effectiveness of
any tocolytic versus placebo being beneficial for neonatal
mortality (table). The point estimates for the active versus
comparisons suggested that calcium channel blockers weremore
effective than all the other classes of tocolytics (fig 4). However,
the credible intervals for the comparisons crossed 1 and
uncertainty in all estimates was considerable. This uncertainty
is reflected in the rankograms shown in fig 4, which suggest
that although calcium channel blockers are the best class for
reducing neonatal mortality, the probability was only 41% and
so indicative of considerable uncertainty. Indeed, there was a
59% probability that they were not the best class for reducing
neonatal mortality. Prostaglandin inhibitors had the next highest
probability of being the best (28%). The probability that calcium
channel blockers were ranked in the top three classes for
reducing neonatal mortality was 85%, followed by betamimetics
(58%), oxytocin receptor blockers (56%), and prostaglandin
inhibitors (54%). The worst performing classes were placebo
(1%) and others (2%), followed by magnesium sulfate, with a
3% probability of being the best class for reducing neonatal
mortality. These results reflect uncertainty around which class
is associated with the fewest neonatal deaths.
Neonatal respiratory distress syndrome
For the outcome neonatal respiratory distress syndrome 42 trials
were included in the network meta-analysis and 37 in the
pairwise meta-analyses. Five trials were excluded from the
pairwisemeta-analyses as they compared treatments fromwithin
the same class. Direct evidence was available for 13 class versus
class pairwise comparisons (see supplementary appendix 2 for
the full results). Heterogeneity between trials was not evident
in any comparison.
Fig 5 shows the posterior median odds ratios (95% credible
intervals) from each pairwise meta-analysis alongside the
posterior median odds ratios for the full suite of 21 class
comparisons available from the network meta-analysis for
respiratory distress syndrome.
The results from the network meta-analysis (table and fig 5)
suggested no evidence of a difference between the classes in
reducing respiratory distress syndrome and no clear effect
compared with placebo. The rankograms (fig 7) suggested that
calcium channel blockers were the best class for reducing
respiratory distress syndrome; however, this probability was
only 47% and so indicative of considerable uncertainty. The
probability that calcium channel blockers were ranked in the
top three classes for reducing respiratory distress syndrome was
80%. The worst performing class was the others, with only an
11% probability of being in the top three classes for reducing
respiratory distress syndrome.
All cause maternal side effects
For the outcome all cause maternal side effects 58 trials were
included in the network meta-analysis and 55 in the pairwise
meta-analyses. Three trials were excluded from the pairwise
meta-analyses as they compared treatments from the same class.
Direct evidence was available for 16 class comparisons versus
class pairwise comparisons.
Fig 6 shows the posterior median odds ratios (95% credible
intervals) from each pairwise meta-analysis (see supplementary
appendix 2 for full results). Heterogeneity was statistically
significant in four of the pairwise meta-analyses: magnesium
sulfate versus prostaglandin inhibitors (n=3 trials), magnesium
sulfate versus betamimetic (n=6), magnesium sulfate versus
calcium channel blockers (n=5), and calcium channel blockers
versus beta mimetics (n=15). The I2 statistic for these four
comparisons was 70% or more.
The network meta-analysis provided treatment effect estimates
for all 21 of the pairwise comparisons that are possible from
the seven drug classes (fig 6). Although the point estimates
indicated that placebo was responsible for fewer maternal side
effects than all active classes, some evidence suggested that
prostaglandin inhibitors and oxytocin receptor blockers were
reasonably well tolerated, with credible intervals consistent with
a reduction in all cause maternal side effects (table). Fig 7
reports the probabilities of every drug class being ranked at each
of the possible seven positions. For all cause maternal side
effects, placebo was ranked first, with a probability of 61%,
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suggesting that women given placebo experienced fewer
maternal side effects. Placebo had a 98% probability of being
ranked in the top three drug classes. The closest active
competitor for reducing all cause maternal side effects was
prostaglandin inhibitors, with a probability of 79%, followed
by oxytocin receptor blockers (70%). Calcium channel blockers
had only a 15% probability of being ranked in the top three drug
classes for maternal side effects.
Other outcomes
The four outcomes analyzed were the most commonly and
consistently reported across the network of trials. It was not
possible to fit either pairwise or network meta-analysis models
to all the outcomes extracted for the systematic review. This
was because of concerns about multiplicity and because of the
small number of studies that consistently reported other
outcomes such as delivery delayed for seven days, delivery
delayed until 37 weeks’ gestation, bronchopulmonary dysplasia,
fetal sepsis, intraventricular hemorrhage, necrotizing
enterocolitis, hyperbilirubinemia, and premature closure of the
ductus arteriosus. Only seven trials reported neonatal composite
outcomes.42 50 62 106 108 117 120 The components of the composites
in each of these trials were different. Because of this and the
way outcomes were reported by individual trials, no overall
result for composite outcome could be analyzed.
Sensitivity analyses
Two sensitivity analyses were carried out for the primary
outcome; restricted to studies at low risk of bias and restricted
to those excluding women at high risk of preterm delivery
(women with multiple gestation and ruptured membranes).
Neither analysis changed the finding that prostaglandin
inhibitors were the best class for delaying preterm delivery by
48 hours. Excluding these trials removed the class other from
the analysis. Class treatment effects were not modified by using
metaregression to explore the effect of length of treatment
delivery (whether it was of short duration or prolonged).
Discussion
Balancing the results relating to benefits and harms, this
systematic review and network meta-analysis on trials of
tocolytics found that prostaglandin inhibitors and calcium
channel blockers have the highest probability of being the best
therapy for preterm delivery on the basis of the four outcomes:
delivery delayed by 48 hours, neonatal mortality, neonatal
respiratory distress syndrome, and maternal side effects (all
causes). Of all the classes considered, prostaglandin inhibitors
had the highest probability of being the most effective class for
delaying preterm delivery and had the most favorable maternal
side effect profile. They did not, however, perform as well for
the neonatal outcomes. When the probability of being ranked
in the top three treatments for delaying delivery was considered,
calcium channel blockers also performed reasonably well, with
a 57% probability of being the best class. For the two neonatal
outcomes, calcium channel blockers also had the highest
probability of being the best class. Uncertainty was, however,
considerable and the benefit from calcium channel blockers
must be considered in light of a somewhat higher probability
of being associated with maternal side effects. To fully
encapsulate the uncertainty arising from the random effects
analysis we also calculated the predicted treatment effect for a
new study on a randomly chosen drug from each class reported
with a 95% prediction interval (see supplementary table 4). For
the outcome of delivery being delayed by 48 hours the credible
intervals were wider; only prostaglandin inhibitors continued
to show a statistically significant beneficial treatment effect.
For maternal side effects, only beta mimetics continued to show
a statistically significant harmful effect, when compared with
placebo. For all other outcomes and all comparisons the
prediction interval crossed the line of null effect, indicating the
true extent of the uncertainty. Weighing the balance of the
results seems to indicate that prostaglandin inhibitors would be
reasonable first-line agents, followed by calcium channel
blockers. This conclusion is true even when the analysis is
limited to studies with the least risk of bias and with the most
clinically homogenous participant populations. In the evidence
base considered here, however, only one, small (n=79) head to
head trial compared prostaglandin inhibitors with a calcium
channel blocker.116 The findings in this trial suggest that
nifedipine (calcium channel blocker) was more effective than
indomethacin (prostaglandin inhibitor) for rapid treatment effect
but that the delay in delivery was similar between women in
both groups who initially responded to treatment. Respiratory
distress syndromewas not reported in the study and two neonatal
deaths occurred in the indomethacin group compared with none
in the nifedipine group.116 Given the small amount of direct
evidence and considerable uncertainty we identified for the
neonatal outcomes, the findings from our networkmeta-analysis
suggest that a head to head trial of these agents is needed to
investigate further the effectiveness, adverse effects, and costs
of these regimens to women. We therefore plan on carrying out
an expected value of information analysis.
The finding that these two classes of medications have the best
outcomes was similar to the findings of a recent pooled
meta-analysis and decision analysis.1 In our analysis, however,
we used a hierarchical class model, which also retains the
individual identity of the within class treatments. Therefore we
were not able to include all the available evidence. The
consistency of findings despite two different methods for
meta-analysis strengthens the argument for these agents being
the first-line choice for tocolysis. Similar to other findings,
tocolysis has been shown to be beneficial for delaying delivery
for at least 48 hours compared with no tocolysis.121
Prostaglandin inhibitors have been studied widely but their use
is limited in practice. Some data indicate a possible association
between neonatal complications and antenatal prostaglandin
inhibitors, including reversible premature closure of the ductus
arteriosus.5 122 123 A Cochrane review of trials on prostaglandin
inhibitors to prevent preterm delivery found that data, albeit
limited, did not show increased adverse neonatal outcomes.8
One of the reasons why prostaglandin inhibitors may be effective
in delaying delivery is because of the large proportion of women
at risk of preterm delivery owing to intrauterine inflammation
and infection.124 Clinically, practitioners who utilize
indomethacin typically limit its use to pregnancies under 32
weeks’ gestation. Because of the limited trial data, in our
networkmeta-analysis we were unable to determine a difference
in the rate of premature closure of the ductus arteriosus with
prostaglandin inhibitors. Indomethacin is commonly utilized to
close a patent ductus in the newborn period.125 126
Network meta-analysis
To our knowledge this is the first application of network
meta-analysis in obstetrics, particularly in tocolysis for preterm
delivery. In obstetrics, where multiple treatment options are
usual, often only compared pairwise, network meta-analysis
has several benefits. We were able to combine all the available
evidence on tocolytic treatments in a single pooled analysis,
even if none had been compared in a direct trial. Network
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meta-analysis makes the assumption of consistency, which
should always be checked.25 We found no evidence of
inconsistency, and empirical studies comparing direct and
indirect evidence have found no systematic differences.127Where
differences have been found, they seem to have been in
situations where the doses or treatment combinations in the
direct and indirect evidence were not comparable.128 129 As long
as the assumption of consistency is fulfilled, all relevant
treatments, even those that are deemed outdated or ineffectual,
can be included in the network to utilize the information on
relative treatment effects and inform the rankings.130
Furthermore, a randomized controlled trial with all of these
arms designed to answer the same questions presented here
would require the randomization of manymore participants.1 131
Strengths and limitations of the study
A strength of our systematic review was the inclusion of several
trials in non-English. These trials are often excluded from
meta-analyses but help to inform the model. We therefore
believe that we have included all relevant randomized controlled
trials on tocolytics up to the search date.
Our analysis was limited by the data in the included studies and
the structure of the reported data. For example, neonatal
mortality was included as an outcome because of its high clinical
importance when evaluating the harms and benefits of tocolytic
therapy. However, few neonatal deaths were reported across
the network of trials. Indeed, even after excluding trials with
zero deaths on both arms, 24/40 trials (60%) reported one or
fewer deaths on at least one arm. Meta-analysis of rare events
is known to be problematic.132 133 This is further compounded
in network meta-analysis if there are also few trials per
comparison, as here for the neonatal mortality outcome (median
3 (range 1-8) trials per comparison). While we understand the
importance of this outcome and realize that excluding these
trials may lead to a problematic overestimation of rates of
neonatal mortality, including these trials in the analysis
invalidated the statistical models. Therefore, extra caution should
be exercised when interpreting the treatment rankings for this
outcome. Furthermore, outcomes were not consistently reported
across the ensemble of trials. For example, the most commonly
reported efficacy outcome was delivery delayed by 48 hours.
However, some studies reported delays at 72 hours or at seven
days. Similarly, some studies reported effectiveness as delivery
after 34 weeks, 36 weeks, or after 38 weeks’ gestation. This is
essentially the same underlying variable, and with better
reporting these data would allow a more thorough synthesis.134
A further finding from our systematic review was the need for
consistent outcome reporting across trials on tocolytics.
We were also unable to utilize the maternal and neonatal data
for several studies that did not include the same outcome
measures as the other trials—that is, they were not included in
the network meta-analysis although they met the eligibility
criteria for the systematic review. This is one of the reasons we
were unable to create a composite outcome. Owing to the way
data were presented by the individual studies, it was impossible
to discern if neonates had more than one outcome, such as
respiratory distress syndrome, intraventricular hemorrhage, and
necrotizing enterocolitis. Different components of a composite
outcome were reported by only seven trials.42 50 62 106 108 117 120
Attempting to extrapolate a composite score for the individual
studies would have essentially duplicated the analysis on
respiratory distress syndrome. An individual participant
meta-analysis might overcome this limitation. It is also possible
that some trials, such as potentially some non-English language
trials, were not included. We diligently searched the accessible
literature on tocolytic studies. The trials included represent the
major accessible published literature on tocolytic therapy.
The results may also be limited by the modeling assumptions.
We preferred a class effect model because of clinical
characteristics and mechanisms of the drugs within the class.
When compared with a distinct treatment effect model, the class
model reported here showed reasonable fit and provided some
support for the assumption of a tocolytic class effect. In addition
to the class model reported, we also explored a model with the
strong assumption of a single class effect, such that all
treatments within a class had the same effect. This model gave
an adequate fit to the data. However it did not allow estimation
of individual treatment effects, which we considered desirable.
We also attempted to relax the assumption of equal within class
variances, by fitting a model assuming each individual treatment
has a distinct effect, but from a common class, with common
class effect and a class specific variance. However, we were
unable to obtain results owing to computational problems from
insufficient data to estimate the variances.
Because of the multitude of doses used for many trials, we were
unable to stratify for dose of drug. However, to deal with
potential concerns about heterogeneity caused by dose, we
carried out a metaregression by treatment duration, which did
not alter the findings. During our systematic review, we assessed
the risk of bias in the retrieved studies. To aid in doing a
sensitivity analysis by risk of bias, we arbitrarily combined the
risk of bias assessments into a composite score. Although this
is often discouraged,135 it was necessary for our planned
sensitivity analysis. To facilitate a more global view of the risk
of bias in the presented studies the full assessments are presented
in the supplementary file. In addition, some of these drugs are
not licensed in some countries and may not be available to
practitioners.
The data contained in the different trials highlight
inconsistencies in reporting of outcomes. Delay of delivery was
consistently reported and thus the model fits this outcome best.
It was more difficult when focusing on maternal safety and on
important neonatal outcomes. Long termmorbidity andmortality
outcomes were inconsistently reported. In future trials, a
standard list of both maternal safety and neonatal short term
and long term outcomes should be reported to allow researchers
to understand the benefits or lack of benefits of tocolytic therapy.
Conclusion
Tocolytic therapy can delay delivery and has an impact on short
term neonatal outcomes. In this network meta-analysis,
prostaglandin inhibitors and calcium channel blockers had the
highest probability of delaying delivery and improving neonatal
outcomes.
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Table
Table 1| Efficacy, neonatal respiratory distress syndrome, and tolerability of tocolytics, using placebo as reference class. Values are
posterior median odds ratios (95% credible intervals) unless stated otherwise
Probability of
being best
Maternal side
effects§
Probability
of being best
Neonatal
respiratory
Probability
of being best
Neonatal
mortality‡
Probability of
being best†
48 hour delay in
delivery*Drug class
distress
syndrome‡
0.61—0.02—0.01—<0.01—Placebo or control
<0.0122.68 (7.51 to
73.67)
0.140.85 (0.50 to 1.45)0.120.62 (0.14 to 2.48)0.012.41 (1.27 to 4.55)Beta mimetic
0.211.63 (0.40 to 6.85)0.200.87 (0.40 to 1.75)0.280.62 (0.04 to 4.63)0.835.39 (2.14 to 12.34)Prostaglandin
inhibitor
0.013.80 (1.02 to
16.92)
0.470.71 (0.37 to 1.43)0.410.39 (0.09 to 1.49)0.062.71 (1.17 to 5.91)Calcium channel
blocker
——0.041.54 (0.55 to 4.71)0.022.79 (0.28 to
31.75)
0.040.93 (0.13 to 6.14)Other
<0.018.15 (2.47 to
27.70)
0.030.99 (0.58 to 1.71)0.030.97 (0.29 to 3.29)0.022.76 (1.58 to 4.94)Magnesium sulfate
0.081.99 (0.61 to 6.94)0.100.89 (0.55 to 1.37)0.130.62 (0.16 to 2.35)0.012.02 (1.10 to 3.80)Oxytocin receptor
blocker (atosiban)
0.103.19 (0.41 to
20.84)
——0.041.91 (0.64 to 5.33)Nitrates
*Odds ratios >1 favor active class.
†Probability that given drug class is best agent to use for given outcome based on rankings over all eight drug classes.
‡Odds ratios <1 favor active class.
§Odds ratios >1 favor placebo.
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Figures
Fig 1 Summary of steps for trial retrieval for network meta-analysis
Fig 2 Graphic representation of tocolytic trials retrieved for network meta-analysis. Lines represent trials comparing two
classes of drug for treatment of preterm delivery. Numbers on lines represent number of trials and total number of participants
in those trials
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Fig 3 Results from network and pairwise meta-analyses for 48 hour delay in delivery. Direct meta-analysis refers to trials
that compared two drug classes directly. In most cases analyses were undertaken using a random effects model. *Fixed
effect meta-analyses. †Single trial. ‡Continuity correction used (0.5 added to each cell of 2×2 table)
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Fig 4 Results from network and pairwise meta-analyses for neonatal mortality. Direct meta-analysis refers to trials that
compared two drug classes directly. In most cases analyses were undertaken using a random effects model. *Fixed effect
meta-analyses. †Single trial. ‡Continuity correction used (0.5 added to each cell of 2×2 table)
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Fig 5 Results from network and pairwise meta-analyses for neonatal respiratory distress syndrome. Direct meta-analysis
refers to trials that compared two drug classes directly. In most cases analyses were undertaken using a random effects
model. *Fixed effect meta-analyses. †Single trial
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Fig 6 Results from network and pairwise meta-analyses for maternal side effects. Direct meta-analysis refers to trials that
compared two drug classes directly. In most cases analyses were undertaken using a random effects model. *Fixed effect
meta-analyses. †Single trial
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Fig 7 Rankings for efficacy of tocolytics and adverse events. Graph displays distribution of probabilities for each outcome.
Ranking indicates probability that drug class is first “best,” second “best,” etc. Dot-dashed line represents 48 hour delay in
delivery. Solid line indicates neonatal mortality. Dashed line indicates respiratory distress syndrome. Dotted line represents
all cause maternal side effects
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